| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/18/2007 | EP1807123A2 A method for improvement of tolerance for therapeutically effective agents delivered by inhalation |
| 07/18/2007 | EP1807118A2 Steroid analogs and characterization and treatment methods |
| 07/18/2007 | EP1807117A2 Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| 07/18/2007 | EP1807113A2 Sustained release of active molecules from polymers topically applied to skin or hair |
| 07/18/2007 | EP1807112A1 Stable aqueous formulation of a platin derivative |
| 07/18/2007 | EP1807107A2 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| 07/18/2007 | EP1807102A2 Compositions and methods for the treatment of obesity and sexual dysfunction |
| 07/18/2007 | EP1807096A1 Bioactive polymers |
| 07/18/2007 | EP1807095A2 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome |
| 07/18/2007 | EP1807094A1 Therapeutic use of cpg oligodeoxynucleotide for skin disease |
| 07/18/2007 | EP1807093A2 Antisense modulation of ptp1b expression |
| 07/18/2007 | EP1807092A2 Biodegradable linkers for molecular therapies |
| 07/18/2007 | EP1807091A1 Novel use of ligands specific to fex-2 polypeptide |
| 07/18/2007 | EP1807090A2 Process for the preparation of ibandronate |
| 07/18/2007 | EP1807089A1 Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mamal and compositions containing the same |
| 07/18/2007 | EP1807088A1 Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives |
| 07/18/2007 | EP1807087A2 Inhibitors of acetylcholinesterase for treating skin diseases |
| 07/18/2007 | EP1807086A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| 07/18/2007 | EP1807085A2 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| 07/18/2007 | EP1807084A2 Use of pyrrolopyrazine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells |
| 07/18/2007 | EP1807083A2 Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| 07/18/2007 | EP1807082A2 Factor xa compounds |
| 07/18/2007 | EP1807081A1 Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
| 07/18/2007 | EP1807080A1 Use of unsaturated quionoline or naphtalene derivatives as medicaments |
| 07/18/2007 | EP1807079A1 Treatment of osteoarthritis and dosing regimen for arzoxifene |
| 07/18/2007 | EP1807078A1 Diaminoalkane aspartic protease inhibitors |
| 07/18/2007 | EP1807077A2 Inhibitors of c-fms kinase |
| 07/18/2007 | EP1807076A1 N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators |
| 07/18/2007 | EP1807075A2 Pi3 kinase gamma inhibitors for the treatment of anaemia |
| 07/18/2007 | EP1807074A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 07/18/2007 | EP1807073A2 Heterocyclic indanone potentiators of metabotropic glutamate receptors |
| 07/18/2007 | EP1807072A1 Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 07/18/2007 | EP1807071A2 Antipyretic compositions and methods |
| 07/18/2007 | EP1807070A1 Combinations of substituted azetidinones and cb1 antagonists |
| 07/18/2007 | EP1807069A1 Methods for regulating weight and size of animals with glycine |
| 07/18/2007 | EP1807068A1 Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkiline agent fr enhanced absorption |
| 07/18/2007 | EP1807067A1 Sphingosine kinase activator and skin disease treating agent comprising the same |
| 07/18/2007 | EP1807066A1 Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
| 07/18/2007 | EP1807065A2 Methods and compositions for treating nephrogenic diabetes insipidus |
| 07/18/2007 | EP1807064A1 Cyanoacrylate monomer formulation containing diiodomethyl-p-tolylsulfone and hydroxydiphenyl ether |
| 07/18/2007 | EP1807063A2 Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
| 07/18/2007 | EP1807062A1 Use of androgens to reduce the likelihood of acquiring or to treat skin aging |
| 07/18/2007 | EP1807061A2 Osteogenic oligonucleotides and uses thereof |
| 07/18/2007 | EP1807059A1 Lercanidipine capsules |
| 07/18/2007 | EP1807058A1 Tablets with site time-controlled gastrointestinal release of active ingredient |
| 07/18/2007 | EP1807057A2 Aliphatic amine polymer salts for tableting |
| 07/18/2007 | EP1807055A1 Process for forming amorphous atorvastatin |
| 07/18/2007 | EP1807051A2 Compositions and methods for stabilizing liposomal camptothecin formulations |
| 07/18/2007 | EP1807049A1 Spontaneously dispersible pharmaceutical compositions |
| 07/18/2007 | EP1807048A1 Reverse micelle composition for delivery of metal cations comprising a diglyceride and a phytosterol and method of preparation |
| 07/18/2007 | EP1807047A2 Sodium ascorbate solubilisate |
| 07/18/2007 | EP1806983A1 Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal |
| 07/18/2007 | EP1725239B1 4-(sulfanyl-pyrimidin-4-ylmethyl)-morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
| 07/18/2007 | EP1718308A4 Methods of modulating neurotrophin-mediated activity |
| 07/18/2007 | EP1711184B1 (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity |
| 07/18/2007 | EP1663981B1 Piperazinyl-quinoline derivatives useful for the treatment of cns disorders |
| 07/18/2007 | EP1644392B1 Rapamycin carbohydrate derivatives |
| 07/18/2007 | EP1603912B1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 07/18/2007 | EP1594854A4 Thiazolyl-based compounds useful as kinase inhibitors |
| 07/18/2007 | EP1558598B1 Triazole compounds for the treatment of dysmenorrhoea |
| 07/18/2007 | EP1526848B1 Opioid-receptor antagonists in transdermal systems having buprenorphine |
| 07/18/2007 | EP1525204B1 Phenylalanine enamide derivatives |
| 07/18/2007 | EP1511462B1 Use of dolichol for the prevention of acute and chronic skin damage caused by exposure to sunlight |
| 07/18/2007 | EP1509537B1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such |
| 07/18/2007 | EP1508566B1 (2s)-2-ethylphenylpropionic acid derivative |
| 07/18/2007 | EP1463545B1 Intraluminal device with a coating containing a therapeutic agent |
| 07/18/2007 | EP1458711B1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3 |
| 07/18/2007 | EP1453514B1 Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma |
| 07/18/2007 | EP1403251B1 Bis(2-aryl-5-pyridyl) derivative |
| 07/18/2007 | EP1403250B1 Bis(5-aryl-2-pyridyl) derivative |
| 07/18/2007 | EP1383482B1 Method for manufacturing a low dose pharmaceutical composition |
| 07/18/2007 | EP1377280B1 Use of bulking agents as satiety agents |
| 07/18/2007 | EP1377269B1 Encapsulated dyes in cosmetic compositions |
| 07/18/2007 | EP1373224B1 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 07/18/2007 | EP1313707B1 Quinoline derivatives as anti-inflammation agents |
| 07/18/2007 | EP1306367B1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 07/18/2007 | EP1285002B1 Regulating lipid levels via the zmax1 or hbm gene |
| 07/18/2007 | EP1278513B1 A core formulation |
| 07/18/2007 | EP1267868B1 Inhibitors of melanocyte tyrosinase as topical skin lighteners |
| 07/18/2007 | EP1249237B1 Topical cosmetic and pharmaceutical composition comprising specific alkoxylated diester of fumaric acid |
| 07/18/2007 | EP1226826B1 Remedies |
| 07/18/2007 | EP1187837B1 Thiazepine inhibitors of hiv-1 integrase |
| 07/18/2007 | EP1181021B1 Use of 4-thiouridine or isomaltitol for the treatment of inflammations and/or haemostasis |
| 07/18/2007 | EP1180097B1 Mutual salt of amlodipine and atorvastatin |
| 07/18/2007 | EP1178780B1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
| 07/18/2007 | EP1150678B1 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 07/18/2007 | EP1143938B1 Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids |
| 07/18/2007 | EP1139753B1 Formulations for treating disease and methods of using same |
| 07/18/2007 | EP1054885B1 Benzisoxazole derivatives having d4-antagonistic activity |
| 07/18/2007 | EP1007044B1 Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies |
| 07/18/2007 | EP0943327B1 Medicinal composition |
| 07/18/2007 | EP0938315B1 Immune response modifier compounds for treatment of th2 mediated and related diseases |
| 07/18/2007 | EP0859751B2 Semi-fluorinated alkanes and their use |
| 07/18/2007 | EP0770140B1 Composition containing nucleic acids and cationic polymers, preparation and uses |
| 07/18/2007 | CN1326982C Transesterification products of corn oil and glycerol and its producing process |
| 07/18/2007 | CN1326876C Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 07/18/2007 | CN1326867C Process for united separation and purification of ursolic acid and oligomeric proanthocyanidin and application thereof |
| 07/18/2007 | CN1326865C 3'-N-oxide, 3'-N-dimethylamine, 9-oxime erythromycin A derivatives |
| 07/18/2007 | CN1326864C 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy)heptanoic acid, preparation process for the same and dauer effect thereof |
| 07/18/2007 | CN1326863C New type azesaccharide compound, their synthesis method and use as immune inhibitor and glycocidase inhibitor |